Company believes it can grow the PNA market beyond the current 5% share it holds of the DNA/RNA synthesis business.
Panagene licensed the right to sell PNA monomers from the Copenhagen Inventor Group (CIG). The company will synthesize, manufacture, and sell peptide nucleic acids (PNA) monomers.
Panagene previously obtained exclusive, worldwide license under CIG’s patents to PNA custom synthesis. “This license from CIG, in addition to the custom PNA synthesis license already granted, shows our continued commitment to expand the field of PNA research,” says Sung Kee Kim, Ph.D., president and CEO of Panagene.
Panagene estimates the PNA market today to be approximately 5% of the DNA/RNA synthesis market but believes that this license will help it grow the business.
